-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Even though the types of monoclonal antibodies for the treatment of inflammatory bowel disease continue to develop, infliximab is still the main treatment drug for inflammatory bowel disease (IBD).
Even though the types of monoclonal antibodies for the treatment of inflammatory bowel disease continue to develop, infliximab is still the main treatment drug for inflammatory bowel disease (IBD).
Researchers conducted a prospective cohort study of 104 patients with IBD at a tertiary medical center in London, Canada.
The results of the study confirmed that compared with patients with active disease (6.
This study confirmed that trough infliximab concentration greater than 8μg/ml in the maintenance phase is highly correlated with histological remission and sustained histological remission.
This study confirmed that trough infliximab concentration greater than 8μg/ml in the maintenance phase is highly correlated with histological remission and sustained histological remission.
Original source:
Aze Wilson.
biomedcentral.
com/articles/10.
1186/s12876-021-01650-7" target="_blank" rel="noopener">High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study.
Leave a message here